• DOI:10.1034/j.1600-0404.2003.02049.x
Corpus ID: 18094044

Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists

@article{Albanese2003DihydroergocriptineIP,
  title={Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists},
  author={A. Albanese and C. Colosimo},
  journal={Acta Neurologica Scandinavica},
  year={2003},
  volume={107}
}

• A. Albanese, C. Colosimo
• Published 2003
• Medicine
• Acta Neurologica Scandinavica

The present paper reviews clinical studies on the use of dihydroergocriptine (DHEC), an ergot derivative with dopamine agonist activity, for the treatment of Parkinson's disease. This compound is a hydrogenated ergot derivative structurally quite similar to bromocriptine, from which it differs because of the hydrogenation in C9–C10 and the lack of bromine in C2. DHEC has a potent D2‐like receptor agonist and a partial D1‐like receptor agonist activity; because of this biochemical profile, it… Expand